IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Merial Limited v Bayer Intellectual Property GmbH [2016] APO 16
Patent Application: 2007341647
Title:Agents for controlling parasites on animals
Patent Applicant: Bayer Intellectual Property GmbH
Opponent: Merial Limited
Delegate: Dr M-A. Fam
Decision Date: 1 April 2016
Hearing Date: 18 February 2016, in Canberra
Catchwords: PATENTS – section 59 – opposition to the grant of a patent – grounds of novelty and inventive step considered – novelty – citation does not disclose all the features of the claims – inventive step – determining the problem requires consideration of the common general knowledge and subsection 7(3) information – problem addressed is the provision of an alternative topical ectoparasiticidal formulation – evidence does not establish that formulation of an active ingredient and three other components is a matter of routine – opposition fails
Representation: Patent applicant: Mr Julian Cooke of counsel instructed by Dr Mathew Lucas and Dr Althea Tsang of Davies Collison Cave
Opponent: Mr Tom Cordiner of counsel instructed by Dr Marcus Caulfield and Dr Toby Thompson of FB Rice
IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Patent Application: 2007341647
Title:Agents for controlling parasites on animals
Patent Applicant: Bayer Intellectual Property GmbH
Date of Decision: 1 April 2016
DECISION
The opposition fails on all grounds. Subject to appeal, I direct the application proceed to grant. Costs according to Schedule 8 are awarded against Merial Limited.
REASONS FOR DECISION
1. Background
The present application was filed by Bayer Healthcare AG on 14 December 2007. Bayer Healthcare AG subsequently changed its name to Bayer Animal Health GmbH and the latter assigned its rights to Bayer Intellectual Property GmbH (Bayer). Following examination, the application was advertised accepted on 3 October 2013.
A notice of opposition was filed by Merial Limited (Merial) on 3 January 2014. A hearing was held in Canberra on 18 February 2016. Bayer was represented by Mr Julian Cooke of counsel instructed by Dr Mathew Lucas and Dr Althea Tsang of Davies Collison Cave. Merial was represented by Mr Tom Cordiner of counsel instructed by Dr Marcus Caulfield and Dr Toby Thompson of FB Rice.
The request for examination in relation to the application was filed on 22 September 2011. Consequently, substantive amendments of the Patents Act 1990 brought about by the Intellectual Property Laws Amendment (Raising the Bar) Act 2012 do not apply to the present application. This includes the amendment to subsection 60 (3A) that allows the Commissioner to refuse a patent application if satisfied on the balance of probabilities that a ground of opposition exists. Any subsequent references to sections of the Patents Act relate to the Patents Act 1990 prior to amendment by the Raising the Bar Act. A similar qualification applies to references to the Patents Regulations 1991.
It is noted that the parties were heard in relation to the opposition to the grant of patent application 2007341648 on 19 February 2016. The present application and 2007341648 relate to similar subject matter. However, each case has its…
Keep reading for free
Create a free CaseChat account to read Merial Limited v Bayer Intellectual Property GmbH and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2016] APO 16
- Decision Date
CaseChat Overview and Summary
Background
Background to the litigation
The procedural history of this case begins with the filing of the patent application by Bayer Healthcare AG on 14 December 2007, which was later assigned to Bayer Intellectual Property GmbH. The application was examined and accepted on 3 October 2013. On 3 January 2014, Merial Limited filed a notice of opposition against the patent application. The opposition was based on several grounds, including novelty, inventive step, manner of manufacture, clarity, fair basis, full description, utility, secret use, and entitlement to the grant of a patent. However, during the hearing, the grounds of opposition pressed were limited to novelty and inventive step. The case was heard in Canberra on 18 February 2016, with Bayer Intellectual Property GmbH represented by Mr Julian Cooke of counsel and Merial Limited represented by Mr Tom Cordiner of counsel. The decision was rendered on 1 April 2016, dismissing the opposition on all grounds.
Decision
Reasons for decision
1. Whether the claims 1-9 of the patent application are novel in light of the prior art.
2. Whether the claims 1-9 of the patent application involve an inventive step in light of the common general knowledge and the prior art.
Held
1. The court concluded that the claims 1-9 of the patent application are novel in light of the prior art. The opposition on this ground was dismissed.
2. The court concluded that the claims 1-9 of the patent application involve an inventive step in light of the common general knowledge and the prior art. The opposition on this ground was also dismissed.
Ratio Decidendi
Legal Principle Established
The court considered the grounds of opposition raised by Merial Limited against Bayer Intellectual Property GmbH's patent application for agents for controlling parasites on animals. The key issues were whether the claims were novel and whether they involved an inventive step. Regarding novelty, the court found that the prior art document AU 2004237454 (D3) did not disclose all the features of the claims, and thus the claims were novel. The court emphasized that the prior art must contain clear and unmistakable directions to achieve what the patentee claims to have invented.
On the issue of inventive step, the court first determined the problem that the specification sought to address. The court concluded that the problem was the provision of an alternative topical ectoparasiticidal formulation comprising an N-phenylpyrazole. The court then considered the common general knowledge and subsection 7(3) information relevant to this problem. The court found that the common general knowledge included knowledge of fipronil, DGME, propylene carbonate, and fatty acid esters as suitable ingredients for topical formulations. However, the court held that combining these ingredients into a formulation was not a matter of routine due to the risk of fipronil crystallizing out of solution, which would result in loss of efficacy.
The court further examined the prior art documents AU 2004237454 (D3), US 6010710 (D8), AU 2002338201 (D11), and the combination of D8 and D11. The court found that none of these documents, when considered with the common general knowledge, demonstrated that the combination of the specific ingredients in the claims would have been obvious to the skilled addressee. Therefore, the court concluded that the claims involved an inventive step.
The ratio decidendi of this decision is that for a combination of known ingredients in a formulation to lack an inventive step, it must be a matter of routine for the skilled addressee to combine them. The court distinguished this case from prior authority by emphasizing the specific risks and challenges associated with formulating the claimed composition.